276 related articles for article (PubMed ID: 22292754)
21. RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation.
Hong KJ; Wu DC; Cheng KH; Chen LT; Hung WC
J Cell Physiol; 2014 Feb; 229(2):191-201. PubMed ID: 23881612
[TBL] [Abstract][Full Text] [Related]
22. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study.
Brummer O; Athar S; Riethdorf L; Löning T; Herbst H
Virchows Arch; 1999 Dec; 435(6):566-73. PubMed ID: 10628798
[TBL] [Abstract][Full Text] [Related]
23. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
24. Comparative gene expression profiling of ADAMs, MMPs, TIMPs, EMMPRIN, EGF-R and VEGFA in low grade meningioma.
Rooprai HK; Martin AJ; King A; Appadu UD; Jones H; Selway RP; Gullan RW; Pilkington GJ
Int J Oncol; 2016 Dec; 49(6):2309-2318. PubMed ID: 27779709
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive gene expression profiling and functional analysis of matrix metalloproteinases and TIMPs, and identification of ADAM-10 gene expression, in a corneal model of epithelial resurfacing.
Gordon GM; Austin JS; Sklar AL; Feuer WJ; LaGier AJ; Fini ME
J Cell Physiol; 2011 Jun; 226(6):1461-70. PubMed ID: 20625997
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.
Suzuki M; Iizasa T; Fujisawa T; Baba M; Yamaguchi Y; Kimura H; Suzuki H
Invasion Metastasis; 1998-1999; 18(3):134-41. PubMed ID: 10474026
[TBL] [Abstract][Full Text] [Related]
27. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours.
Giantin M; Aresu L; Benali S; Aricò A; Morello EM; Martano M; Vascellari M; Castagnaro M; Lopparelli RM; Zancanella V; Granato A; Mutinelli F; Dacasto M
J Comp Pathol; 2012 Nov; 147(4):419-29. PubMed ID: 22520817
[TBL] [Abstract][Full Text] [Related]
28. A Hypothesis for the Role of RECK in Angiogenesis.
Gutiérrez J; Droppelmann CA; Salsoso R; Westermeier F; Toledo F; Salomon C; Sanhueza C; Pardo F; Leiva A; Sobrevia L
Curr Vasc Pharmacol; 2016; 14(1):106-15. PubMed ID: 26463982
[TBL] [Abstract][Full Text] [Related]
29. Endogenous and synthetic MMP inhibitors in CNS physiopathology.
Baranger K; Rivera S; Liechti FD; Grandgirard D; Bigas J; Seco J; Tarrago T; Leib SL; Khrestchatisky M
Prog Brain Res; 2014; 214():313-51. PubMed ID: 25410364
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer.
Thomas P; Khokha R; Shepherd FA; Feld R; Tsao MS
J Pathol; 2000 Feb; 190(2):150-6. PubMed ID: 10657012
[TBL] [Abstract][Full Text] [Related]
31. Cobalt chloride-induced hypoxia modulates the invasive potential and matrix metalloproteinases of primary and metastatic breast cancer cells.
Fu OY; Hou MF; Yang SF; Huang SC; Lee WY
Anticancer Res; 2009 Aug; 29(8):3131-8. PubMed ID: 19661326
[TBL] [Abstract][Full Text] [Related]
32. A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.
Matusiak N; Castelli R; Tuin AW; Overkleeft HS; Wisastra R; Dekker FJ; Prély LM; Bischoff R; van Waarde A; Dierckx RA; Elsinga PH
Bioorg Med Chem; 2015 Jan; 23(1):192-202. PubMed ID: 25438884
[TBL] [Abstract][Full Text] [Related]
33. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors.
Nagase H; Brew K
Biochem Soc Symp; 2003; (70):201-12. PubMed ID: 14587293
[TBL] [Abstract][Full Text] [Related]
34. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer.
Groblewska M; Siewko M; Mroczko B; Szmitkowski M
Folia Histochem Cytobiol; 2012 Apr; 50(1):12-9. PubMed ID: 22532131
[TBL] [Abstract][Full Text] [Related]
35. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
36. Spatio-temporal expression profile of matrix metalloproteinase (Mmp) modulators Reck and Sparc during the rat ovarian dynamics.
Levin G; Coelho TM; Nóbrega NG; Trombetta-Lima M; Sogayar MC; Carreira ACO
Reprod Biol Endocrinol; 2018 Nov; 16(1):116. PubMed ID: 30424792
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
Matsunaga Y; Koda M; Murawaki Y
Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
[TBL] [Abstract][Full Text] [Related]
38. Tomatidine inhibits invasion of human lung adenocarcinoma cell A549 by reducing matrix metalloproteinases expression.
Yan KH; Lee LM; Yan SH; Huang HC; Li CC; Lin HT; Chen PS
Chem Biol Interact; 2013 May; 203(3):580-7. PubMed ID: 23566884
[TBL] [Abstract][Full Text] [Related]
39. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1.
Elkington PT; Nuttall RK; Boyle JJ; O'Kane CM; Horncastle DE; Edwards DR; Friedland JS
Am J Respir Crit Care Med; 2005 Dec; 172(12):1596-604. PubMed ID: 16141443
[TBL] [Abstract][Full Text] [Related]
40. RECK, a novel matrix metalloproteinase regulator.
Meng N; Li Y; Zhang H; Sun XF
Histol Histopathol; 2008 Aug; 23(8):1003-10. PubMed ID: 18498076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
